董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Carl Gordon | 男 | Director | 54 | 未披露 | 未持股 | 2019-04-18 |
| Robert Adelman | 男 | Director | 56 | 未披露 | 未持股 | 2019-04-18 |
| Simeon George | 男 | Director | 41 | 未披露 | 未持股 | 2019-04-18 |
| Hongbo Lu | 女 | Director | 48 | 未披露 | 未持股 | 2019-04-18 |
| Jacob M. Chacko | 男 | Director | 40 | 43.49万美元 | 未持股 | 2019-04-18 |
| Yishan Li | 男 | Head of Turning Point Therapeutics, Asia, and Director | 54 | 209.71万美元 | 未持股 | 2019-04-18 |
| Jingrong Jean Cui | 女 | Chief Scientific Officer and Chair of the Board | 55 | 743.86万美元 | 未持股 | 2019-04-18 |
| Athena Countouriotis | 女 | President, Chief Executive Officer and Director | 47 | 866.38万美元 | 未持股 | 2019-04-18 |
| Sheila Gujrathi | 女 | Director | 48 | 3.00万美元 | 未持股 | 2019-04-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Annette North | 女 | Executive Vice President, General Counsel and Secretary | 53 | 未披露 | 未持股 | 2019-04-18 |
| Brian Baker | 男 | Vice President of Finance and Administration | 52 | 42.83万美元 | 未持股 | 2019-04-18 |
| Jingrong Jean Cui | 女 | Chief Scientific Officer and Chair of the Board | 55 | 743.86万美元 | 未持股 | 2019-04-18 |
| Athena Countouriotis | 女 | President, Chief Executive Officer and Director | 47 | 866.38万美元 | 未持股 | 2019-04-18 |
董事简历
中英对照 | 中文 | 英文- Carl Gordon
-
Carl Gordon，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。他曾担任OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管（1998年以来）。他目前担任Adicet Bio, Inc.（纳斯达克代码：ACET）， ArriVent Biopharma Inc.（纳斯达克代码：AVBP）， Compass Therapeutics, Inc.（纳斯达克代码：CMPX）， Keros Therapeutics, Inc.（纳斯达克代码：KROS）和Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）以及几家私人公司的董事会成员。他曾任职于Alector, Inc.（纳斯达克代码：ALEC）， Gemini Therapeutics, Inc.（前纳斯达克代码：GMTX，与Disc Medicine, Inc.合并），Kinnate Biopharma Inc.（纳斯达克代码：KNTE）， ORIC Pharmaceuticals, Inc.（纳斯达克代码：ORIC）， Passage Bio, Inc.（纳斯达克代码：PASG）， precintics Inc.（前纳斯达克代码：PRVL，被Eli Lilly收购），SpringWorks Therapeutics, Inc.（纳斯达克代码：SWTX）， Theseus Pharmaceuticals, Inc.（前纳斯达克代码：SWTX）的董事会。THRX（被Concentra Biosciences LLC收购）和Turning Point Therapeutics, Inc.（前纳斯达克股票代码：TPTX，被Bristol Myers Squibb Co.收购）。他持有Harvard College的化学学士学位，Massachusetts Institute of Technology的分子生物学博士学位，也是the Rockefeller University的研究员。
Carl Gordon,has served on Mbx Biosciences, Inc. board of directors since July 2020. He has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr. Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc. (Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr. Gordon previously served on the boards of Alector, Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University. - Carl Gordon，自2020年7月起担任Mbx Biosciences, Inc.董事会成员。他曾担任OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管（1998年以来）。他目前担任Adicet Bio, Inc.（纳斯达克代码：ACET）， ArriVent Biopharma Inc.（纳斯达克代码：AVBP）， Compass Therapeutics, Inc.（纳斯达克代码：CMPX）， Keros Therapeutics, Inc.（纳斯达克代码：KROS）和Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）以及几家私人公司的董事会成员。他曾任职于Alector, Inc.（纳斯达克代码：ALEC）， Gemini Therapeutics, Inc.（前纳斯达克代码：GMTX，与Disc Medicine, Inc.合并），Kinnate Biopharma Inc.（纳斯达克代码：KNTE）， ORIC Pharmaceuticals, Inc.（纳斯达克代码：ORIC）， Passage Bio, Inc.（纳斯达克代码：PASG）， precintics Inc.（前纳斯达克代码：PRVL，被Eli Lilly收购），SpringWorks Therapeutics, Inc.（纳斯达克代码：SWTX）， Theseus Pharmaceuticals, Inc.（前纳斯达克代码：SWTX）的董事会。THRX（被Concentra Biosciences LLC收购）和Turning Point Therapeutics, Inc.（前纳斯达克股票代码：TPTX，被Bristol Myers Squibb Co.收购）。他持有Harvard College的化学学士学位，Massachusetts Institute of Technology的分子生物学博士学位，也是the Rockefeller University的研究员。
- Carl Gordon,has served on Mbx Biosciences, Inc. board of directors since July 2020. He has served as a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm, since 1998. Dr. Gordon currently serves on the boards of directors of Adicet Bio, Inc. (Nasdaq: ACET), ArriVent Biopharma Inc. (Nasdaq: AVBP), Compass Therapeutics, Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS), and Terns Pharmaceuticals, Inc. (Nasdaq: TERN), as well as several private companies. Dr. Gordon previously served on the boards of Alector, Inc. (Nasdaq: ALEC), Gemini Therapeutics, Inc. (formerly Nasdaq: GMTX which merged with Disc Medicine, Inc.), Kinnate Biopharma Inc. (Nasdaq: KNTE), ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), Passage Bio, Inc. (Nasdaq: PASG), Prevail Therapeutics Inc. (formerly Nasdaq: PRVL which was acquired by Eli Lilly), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), Theseus Pharmaceuticals, Inc. (formerly Nasdaq: THRX which was acquired by Concentra Biosciences LLC), and Turning Point Therapeutics, Inc. (formerly Nasdaq: TPTX which was acquired by Bristol Myers Squibb Co.). Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
- Robert Adelman
-
Robert Adelman自2015年1月以来一直担任我们的董事会成员。他曾一直担任Venbio Partners公司（生命科学投资公司，他于2009年共同创立的公司）的管理合伙人（2010年以来）。共同创立Venbio公司之前，他曾任职OrbiMed Advisors公司（从2002年到2008年），在那里他曾领导三个风险投资基金的私人和上市公司的多种投资。此外，Adelman博士还曾在ApellisPharmaceuticals，Inc.、Turning PointTherapeutics，Inc.、Seragon和Aragon的董事会任职。Adelman博士在加州大学伯克利分校（University of California at Berkeley）获得学士学位，在耶鲁大学（Yale University）获得医学博士学位，在康奈尔大学医学中心（Cornell University Medical Center）进行住院实习，并在纽约和新泽西从事外科手术。
Robert Adelman has served as a member of our board of directors since January 2015. Since 2010 Dr. Adelman has served as Managing Partner at venBio Partners LLC, or venBio, a life sciences investment firm, which he co-founded in 2009. Prior to co-founding venBio, Dr. Adelman worked at OrbiMed Advisors LLC from 2002 to 2008 where he led numerous investments in both private and public companies across three venture capital funds. In addition, Dr. Adelman previously served on the boards of directors of Apellis Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Seragon and Aragon. Dr. Adelman received his B.A. from University of California at Berkeley and his M.D. from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. - Robert Adelman自2015年1月以来一直担任我们的董事会成员。他曾一直担任Venbio Partners公司（生命科学投资公司，他于2009年共同创立的公司）的管理合伙人（2010年以来）。共同创立Venbio公司之前，他曾任职OrbiMed Advisors公司（从2002年到2008年），在那里他曾领导三个风险投资基金的私人和上市公司的多种投资。此外，Adelman博士还曾在ApellisPharmaceuticals，Inc.、Turning PointTherapeutics，Inc.、Seragon和Aragon的董事会任职。Adelman博士在加州大学伯克利分校（University of California at Berkeley）获得学士学位，在耶鲁大学（Yale University）获得医学博士学位，在康奈尔大学医学中心（Cornell University Medical Center）进行住院实习，并在纽约和新泽西从事外科手术。
- Robert Adelman has served as a member of our board of directors since January 2015. Since 2010 Dr. Adelman has served as Managing Partner at venBio Partners LLC, or venBio, a life sciences investment firm, which he co-founded in 2009. Prior to co-founding venBio, Dr. Adelman worked at OrbiMed Advisors LLC from 2002 to 2008 where he led numerous investments in both private and public companies across three venture capital funds. In addition, Dr. Adelman previously served on the boards of directors of Apellis Pharmaceuticals, Inc., Turning Point Therapeutics, Inc., Seragon and Aragon. Dr. Adelman received his B.A. from University of California at Berkeley and his M.D. from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey.
- Simeon George
-
Simeon George自2020年2月以来一直担任我们的董事会成员。自2020年9月以来，George博士一直担任SR One Capital Management，LP的首席执行官。George博士曾于2019年1月至2020年9月担任S.R.One，Limited的首席执行官，最初于2007年9月加入该公司担任助理。从2006年到2007年，George博士是贝恩公司（Bain&Company）的顾问，2004年他是高盛（Goldman Sachs）的投资银行家。George博士目前在以下上市公司的董事会任职:CRISPR Therapeutics（自2015年4月起），Turning PointTherapeutics，Inc.（自2017年5月起）和NKARTA（自2020年2月起，之前从2015年7月至2017年9月）。George博士还曾担任Principia BiopharmaInc.（从2011年2月到2020年9月被收购），Progyny（从2012年5月到2019年10月），Htg分子诊断公司（从2011年6月到2015年10月）和GenoceaBiosciences，Inc.（从2009年2月到2014年12月）的董事会成员。George博士在约翰霍普金斯大学（Johns Hopkins University）获得神经科学学士学位，在那里他毕业于Phi Beta Kappa。他在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学博士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位（Mayer Scholar）。
Simeon George has served on Progyny, Inc. board of directors since May 2012. Dr. George joined S.R. One, Limited in September 2007 as an Associate and later became Partner, and since February 2019 has served as Chief Executive Officer. From 2006 to 2007 Dr. George was a consultant at Bain & Company, and in 2004 he was an investment banker at Goldman Sachs and Merrill Lynch. Dr. George currently serves on the boards of directors of the following public companies: Principia Biopharma Inc. since February 2011 CRISPR Therapeutics (since April 2015) and Turning Point Therapeutics, Inc. (since May 2017). Dr. George also served on the boards of directors of HTG Molecular Diagnostics, Inc., from June 2011 until October 2015 and Genocea Biosciences, Inc., from February 2009 to December 2014. Dr. George received his B.A. in neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa. He received his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania. - Simeon George自2020年2月以来一直担任我们的董事会成员。自2020年9月以来，George博士一直担任SR One Capital Management，LP的首席执行官。George博士曾于2019年1月至2020年9月担任S.R.One，Limited的首席执行官，最初于2007年9月加入该公司担任助理。从2006年到2007年，George博士是贝恩公司（Bain&Company）的顾问，2004年他是高盛（Goldman Sachs）的投资银行家。George博士目前在以下上市公司的董事会任职:CRISPR Therapeutics（自2015年4月起），Turning PointTherapeutics，Inc.（自2017年5月起）和NKARTA（自2020年2月起，之前从2015年7月至2017年9月）。George博士还曾担任Principia BiopharmaInc.（从2011年2月到2020年9月被收购），Progyny（从2012年5月到2019年10月），Htg分子诊断公司（从2011年6月到2015年10月）和GenoceaBiosciences，Inc.（从2009年2月到2014年12月）的董事会成员。George博士在约翰霍普金斯大学（Johns Hopkins University）获得神经科学学士学位，在那里他毕业于Phi Beta Kappa。他在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学博士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位（Mayer Scholar）。
- Simeon George has served on Progyny, Inc. board of directors since May 2012. Dr. George joined S.R. One, Limited in September 2007 as an Associate and later became Partner, and since February 2019 has served as Chief Executive Officer. From 2006 to 2007 Dr. George was a consultant at Bain & Company, and in 2004 he was an investment banker at Goldman Sachs and Merrill Lynch. Dr. George currently serves on the boards of directors of the following public companies: Principia Biopharma Inc. since February 2011 CRISPR Therapeutics (since April 2015) and Turning Point Therapeutics, Inc. (since May 2017). Dr. George also served on the boards of directors of HTG Molecular Diagnostics, Inc., from June 2011 until October 2015 and Genocea Biosciences, Inc., from February 2009 to December 2014. Dr. George received his B.A. in neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa. He received his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania.
- Hongbo Lu
-
Hongbo Lu自2020年4月以来一直担任我们的董事会成员。她自2021年1月起担任风险投资公司Vivo Capital的管理合伙人。她此前曾于2017年1月至2020年12月担任风险投资公司Lilly Asia Ventures的管理合伙人。2011年6月至2016年10月，她曾担任OrbiMed Advisors LLC的董事总经理。陆博士目前担任几家私人生物技术公司的董事会成员，例如PINS Medical，Inc.，Elpiscience和Geneception。她曾于2017年5月至2019年5月担任上市公司董事会成员，包括上市生物技术公司Turning PointTherapeutics，Inc.，并于2018年5月至2019年2月担任上市生物技术公司Avedro，Inc.的董事会成员。陆博士在中国清华大学获得材料科学与工程本科学位，在华盛顿大学获得生物工程博士学位，在加州大学伯克利分校获得工商管理硕士学位。
Hongbo Lu has served as a member of board of directors since November 2022. Dr. Lu is the Managing Member of NEXTBio Capital, a biotech investment firm. Dr. Lu. was previoly a Managing Partner at Vivo Capital LLC from December 2020 until January 2024. Previoly, Dr. Lu served as a Managing Partner at Lilly Asia Ventures from January 2017 until December 2020 ("LAV"). Prior to her role at LAV, she was affiliated with OrbiMed Advisors from June 2011 until October 2016, lastly as its Managing Director. Dr. Lu previoly served on the boards of directors of public companies including Turning Point Therapeutics, Inc. (Nasdaq: TPTX, acquired by Bristol Myers Squibb), Crown Bioscience Inc. (6554.TT, acquired by JSR), Avedro Inc. (Nasdaq: AVDR, acquired by Glaukos) and Terns Pharmaceuticals Inc. (Nasdaq: TERN, from April 2020 until Augt 2025). She currently serves on the board of Arrowhead Pharmaceuticals (Nasdaq: ARWR, since March 2024). Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and was previoly involved in biotech start up Zyomyx in the San Francisco Bay Area. Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an M.B.A. from the Haas School of Biness at the University of California, Berkeley, and graduated with honors from Tsinghua University. - Hongbo Lu自2020年4月以来一直担任我们的董事会成员。她自2021年1月起担任风险投资公司Vivo Capital的管理合伙人。她此前曾于2017年1月至2020年12月担任风险投资公司Lilly Asia Ventures的管理合伙人。2011年6月至2016年10月，她曾担任OrbiMed Advisors LLC的董事总经理。陆博士目前担任几家私人生物技术公司的董事会成员，例如PINS Medical，Inc.，Elpiscience和Geneception。她曾于2017年5月至2019年5月担任上市公司董事会成员，包括上市生物技术公司Turning PointTherapeutics，Inc.，并于2018年5月至2019年2月担任上市生物技术公司Avedro，Inc.的董事会成员。陆博士在中国清华大学获得材料科学与工程本科学位，在华盛顿大学获得生物工程博士学位，在加州大学伯克利分校获得工商管理硕士学位。
- Hongbo Lu has served as a member of board of directors since November 2022. Dr. Lu is the Managing Member of NEXTBio Capital, a biotech investment firm. Dr. Lu. was previoly a Managing Partner at Vivo Capital LLC from December 2020 until January 2024. Previoly, Dr. Lu served as a Managing Partner at Lilly Asia Ventures from January 2017 until December 2020 ("LAV"). Prior to her role at LAV, she was affiliated with OrbiMed Advisors from June 2011 until October 2016, lastly as its Managing Director. Dr. Lu previoly served on the boards of directors of public companies including Turning Point Therapeutics, Inc. (Nasdaq: TPTX, acquired by Bristol Myers Squibb), Crown Bioscience Inc. (6554.TT, acquired by JSR), Avedro Inc. (Nasdaq: AVDR, acquired by Glaukos) and Terns Pharmaceuticals Inc. (Nasdaq: TERN, from April 2020 until Augt 2025). She currently serves on the board of Arrowhead Pharmaceuticals (Nasdaq: ARWR, since March 2024). Dr. Lu started her Wall Street career as a biotech analyst at Piper Jaffray & Co. and was previoly involved in biotech start up Zyomyx in the San Francisco Bay Area. Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an M.B.A. from the Haas School of Biness at the University of California, Berkeley, and graduated with honors from Tsinghua University.
- Jacob M. Chacko
-
JacobM.Chacko自2018年5月起担任我们的首席执行官兼董事会成员，自2019年5月起担任我们的总裁。2014年5月至2018年2月，他担任精密肿瘤公司Ignyta，Inc.的首席财务官，该公司于2018年2月被制药和诊断公司Roche Holding AG收购。2008年8月至2014年5月，Chacko博士担任私募股权投资公司TPG Capital的Vice President。在此之前，Chacko博士是麦肯锡公司（McKinsey&Company）梦百合客户的顾问，这是一家管理咨询公司。他目前任职于制药公司Turning PointTherapeutics，Inc.和制药公司4DMolecularTherapeutics，Inc.的董事会。Chacko博士在加州大学洛杉矶分校（UCLA）获得工商管理硕士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。从牛津大学获得生物学学士学位，从南加州大学获得老年学学士学位。
Jacob M. Chacko has served as our Chief Executive Officer and as a member of our board of directors since May 2018 and as our President since May 2019. From May 2014 to February 2018 he served as Chief Financial Officer of Ignyta, Inc., a precision oncology company that was acquired in February 2018 by Roche Holding AG, a pharmaceuticals and diagnostics company. From August 2008 to May 2014 Dr. Chacko served as Vice President at TPG Capital, a private equity investment firm. Prior to that, Dr. Chacko was a consultant to healthcare clients at McKinsey & Company, a management consulting firm. He currently serves on the board of directors of Turning Point Therapeutics, Inc., a pharmaceutical company, and 4D Molecular Therapeutics, Inc., a pharmaceutical company. Dr. Chacko received an M.D. from UCLA, an M.B.A. from Harvard Business School, an M.Sc. from Oxford University and a B.A. in biology and B.S. in gerontology from the University of Southern California. - JacobM.Chacko自2018年5月起担任我们的首席执行官兼董事会成员，自2019年5月起担任我们的总裁。2014年5月至2018年2月，他担任精密肿瘤公司Ignyta，Inc.的首席财务官，该公司于2018年2月被制药和诊断公司Roche Holding AG收购。2008年8月至2014年5月，Chacko博士担任私募股权投资公司TPG Capital的Vice President。在此之前，Chacko博士是麦肯锡公司（McKinsey&Company）梦百合客户的顾问，这是一家管理咨询公司。他目前任职于制药公司Turning PointTherapeutics，Inc.和制药公司4DMolecularTherapeutics，Inc.的董事会。Chacko博士在加州大学洛杉矶分校（UCLA）获得工商管理硕士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。从牛津大学获得生物学学士学位，从南加州大学获得老年学学士学位。
- Jacob M. Chacko has served as our Chief Executive Officer and as a member of our board of directors since May 2018 and as our President since May 2019. From May 2014 to February 2018 he served as Chief Financial Officer of Ignyta, Inc., a precision oncology company that was acquired in February 2018 by Roche Holding AG, a pharmaceuticals and diagnostics company. From August 2008 to May 2014 Dr. Chacko served as Vice President at TPG Capital, a private equity investment firm. Prior to that, Dr. Chacko was a consultant to healthcare clients at McKinsey & Company, a management consulting firm. He currently serves on the board of directors of Turning Point Therapeutics, Inc., a pharmaceutical company, and 4D Molecular Therapeutics, Inc., a pharmaceutical company. Dr. Chacko received an M.D. from UCLA, an M.B.A. from Harvard Business School, an M.Sc. from Oxford University and a B.A. in biology and B.S. in gerontology from the University of Southern California.
- Yishan Li
-
Yishan Li是Turning Point Therapeutics的联合创始人，自2013年10月起担任董事会成员，2015年10月至2018年9月担任董事长。李博士已从我们的董事会辞职，并于本次发行完成后生效。2018年9月，李博士开始担任亚洲Turning Point Therapeutics的负责人。李博士于2019年4月辞去了在我们的工作，于2019年5月31日生效。从2013年10月至2018年9月，李博士担任我们的首席执行官。李博士还于2013年10月至2018年4月担任我们的总裁。2003年至2013年，李博士先后担任生物技术公司Epitomics，Inc.的生命科学Vice President、高级副总裁，和执行Vice President，之后该公司被ABCAM，plc收购。从2001年到2003年，李博士担任Kenson Ventures，LLC的Vice President。从2002年到2009年，李博士一直担任SABIOSciences Corporation的董事，直到该公司于2000年被QiagenN.V.收购。李博士曾担任Dain Rauscher Wessels，LLC的夏季公司银行助理。从1997年到1999年，李博士担任Santa Cruz Biotechnology，Inc.的集团领导。从1994年到1997年，李博士是加州大学伯克利分校的博士后。从2012年至2018年4月，李博士一直担任营养基因组学公司GB HealthWatch的董事会成员。李博士在加州大学伯克利分校哈斯商学院获得工商管理硕士学位，在俄亥俄州立大学获得博士学位，在中国科学技术大学获得学士学位。
Yishan Li is a co-founder of Turning Point Therapeutics, and has served as a member of our board of directors since October 2013 serving as Chairman from October 2015 until September 2018. Dr. Li has resigned from our board of directors contingent and effective upon the closing of this offering. In September 2018 Dr. Li began serving as Head of Turning Point Therapeutics, Asia. In April 2019 Dr. Li resigned his employment with us effective May 31 2019. From October 2013 until September 2018 Dr. Li served as our Chief Executive Officer. Dr. Li also served as our President from October 2013 until April 2018. From 2003 until 2013 Dr. Li served as Vice President of Life Sciences, then Senior Vice President, and then Executive Vice President at Epitomics, Inc., a biotechnology company, before the company was acquired by Abcam, plc. From 2001 until 2003 Dr. Li served as Vice President at Kenson Ventures, LLC. From 2002 until 2009 Dr. Li served on the board of directors of SABiosciences Corporation until it was acquired by QIAGEN N.V. In 2000 Dr. Li served as a summer corporate banking associate at Dain Rauscher Wessels, LLC. From 1997 until 1999 Dr. Li served as a group leader at Santa Cruz Biotechnology, Inc. From 1994 until 1997 Dr. Li was a postdoctoral fellow at the University of California Berkeley. From 2012 to April 2018 Dr. Li has served as a member of the board of directors of GB Healthwatch, a nutritional genomics company. Dr. Li received his M.B.A. from Haas School of Business at the University of California Berkeley, his Ph.D. from The Ohio State University and his B.S. from the University of Science and Technology of China. - Yishan Li是Turning Point Therapeutics的联合创始人，自2013年10月起担任董事会成员，2015年10月至2018年9月担任董事长。李博士已从我们的董事会辞职，并于本次发行完成后生效。2018年9月，李博士开始担任亚洲Turning Point Therapeutics的负责人。李博士于2019年4月辞去了在我们的工作，于2019年5月31日生效。从2013年10月至2018年9月，李博士担任我们的首席执行官。李博士还于2013年10月至2018年4月担任我们的总裁。2003年至2013年，李博士先后担任生物技术公司Epitomics，Inc.的生命科学Vice President、高级副总裁，和执行Vice President，之后该公司被ABCAM，plc收购。从2001年到2003年，李博士担任Kenson Ventures，LLC的Vice President。从2002年到2009年，李博士一直担任SABIOSciences Corporation的董事，直到该公司于2000年被QiagenN.V.收购。李博士曾担任Dain Rauscher Wessels，LLC的夏季公司银行助理。从1997年到1999年，李博士担任Santa Cruz Biotechnology，Inc.的集团领导。从1994年到1997年，李博士是加州大学伯克利分校的博士后。从2012年至2018年4月，李博士一直担任营养基因组学公司GB HealthWatch的董事会成员。李博士在加州大学伯克利分校哈斯商学院获得工商管理硕士学位，在俄亥俄州立大学获得博士学位，在中国科学技术大学获得学士学位。
- Yishan Li is a co-founder of Turning Point Therapeutics, and has served as a member of our board of directors since October 2013 serving as Chairman from October 2015 until September 2018. Dr. Li has resigned from our board of directors contingent and effective upon the closing of this offering. In September 2018 Dr. Li began serving as Head of Turning Point Therapeutics, Asia. In April 2019 Dr. Li resigned his employment with us effective May 31 2019. From October 2013 until September 2018 Dr. Li served as our Chief Executive Officer. Dr. Li also served as our President from October 2013 until April 2018. From 2003 until 2013 Dr. Li served as Vice President of Life Sciences, then Senior Vice President, and then Executive Vice President at Epitomics, Inc., a biotechnology company, before the company was acquired by Abcam, plc. From 2001 until 2003 Dr. Li served as Vice President at Kenson Ventures, LLC. From 2002 until 2009 Dr. Li served on the board of directors of SABiosciences Corporation until it was acquired by QIAGEN N.V. In 2000 Dr. Li served as a summer corporate banking associate at Dain Rauscher Wessels, LLC. From 1997 until 1999 Dr. Li served as a group leader at Santa Cruz Biotechnology, Inc. From 1994 until 1997 Dr. Li was a postdoctoral fellow at the University of California Berkeley. From 2012 to April 2018 Dr. Li has served as a member of the board of directors of GB Healthwatch, a nutritional genomics company. Dr. Li received his M.B.A. from Haas School of Business at the University of California Berkeley, his Ph.D. from The Ohio State University and his B.S. from the University of Science and Technology of China.
- Jingrong Jean Cui
-
Jingrong Jean Cui是Turning Point Therapeutics的联合创始人，自2013年10月以来一直担任我们的首席科学官和董事会成员。崔博士于2018年4月至2019年1月担任我们的总裁。2018年9月，崔博士成为我们的董事会主席。从2003年到2013年，崔博士是辉瑞公司的高级首席科学家，然后是副研究员。从1999年到2003年，崔博士担任Sugen，Inc.（一家制药公司）的项目负责人和集团负责人。从1997年到1999年，崔博士是Corvas International，Inc.的研究科学家。从1995年到1997年，崔博士是Glycomed，Inc.的研究科学家。从1994年到1995年，崔博士是劳伦斯伯克利国家实验室和加州大学伯克利分校的博士后。崔博士在俄亥俄州立大学获得博士学位，并在中国科学技术大学获得工商管理硕士学位。
Jingrong Jean Cui is a co-founder of Turning Point Therapeutics, and has served as our Chief Scientific Officer and a member of our board of directors since October 2013. Dr. Cui served as our President from April 2018 until January 2019. In September 2018 Dr. Cui became Chair of our board of directors. From 2003 until 2013 Dr. Cui was Senior Principal Scientist and then Associate Research Fellow at Pfizer. From 1999 until 2003 Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation. From 1997 until 1999 Dr. Cui was a research scientist at Corvas International, Inc. From 1995 until 1997 Dr. Cui was a research scientist at Glycomed, Inc. From 1994 until 1995 Dr. Cui was a postdoctoral fellow at Lawrence Berkeley National Laboratory and the University of California Berkeley. Dr. Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the University of Science and Technology of China. - Jingrong Jean Cui是Turning Point Therapeutics的联合创始人，自2013年10月以来一直担任我们的首席科学官和董事会成员。崔博士于2018年4月至2019年1月担任我们的总裁。2018年9月，崔博士成为我们的董事会主席。从2003年到2013年，崔博士是辉瑞公司的高级首席科学家，然后是副研究员。从1999年到2003年，崔博士担任Sugen，Inc.（一家制药公司）的项目负责人和集团负责人。从1997年到1999年，崔博士是Corvas International，Inc.的研究科学家。从1995年到1997年，崔博士是Glycomed，Inc.的研究科学家。从1994年到1995年，崔博士是劳伦斯伯克利国家实验室和加州大学伯克利分校的博士后。崔博士在俄亥俄州立大学获得博士学位，并在中国科学技术大学获得工商管理硕士学位。
- Jingrong Jean Cui is a co-founder of Turning Point Therapeutics, and has served as our Chief Scientific Officer and a member of our board of directors since October 2013. Dr. Cui served as our President from April 2018 until January 2019. In September 2018 Dr. Cui became Chair of our board of directors. From 2003 until 2013 Dr. Cui was Senior Principal Scientist and then Associate Research Fellow at Pfizer. From 1999 until 2003 Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation. From 1997 until 1999 Dr. Cui was a research scientist at Corvas International, Inc. From 1995 until 1997 Dr. Cui was a research scientist at Glycomed, Inc. From 1994 until 1995 Dr. Cui was a postdoctoral fellow at Lawrence Berkeley National Laboratory and the University of California Berkeley. Dr. Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the University of Science and Technology of China.
- Athena Countouriotis
-
Athena Countouriotis自2018年10月起担任Turning Point医疗公司的首席执行官和董事会成员，并于2018年5月至2018年9月期间担任Turning Point医疗的首席医疗官。Countouriotis博士于2017年6月至2018年5月担任Adverum生物科技公司高级副总裁兼首席医疗官，在此之前于2015年1月至2017年5月担任奥洛兹美医疗公司高级副总裁兼首席医疗官。Countouriotis博士还从2012年2月起担任Ambit Biosciences Corporation的首席医疗官，直到2014年11月Ambit被Daiichi Sankyo公司收购。在她职业生涯的早期，Countouriotis博士曾领导辉瑞公司和百时美施贵宝公司内的多个肿瘤治疗临床开发组织。Countouriotis博士目前在Iovance Biotherapeutics，Inc.和Trovagene，Inc.的董事会任职，这两家公司都是上市的肿瘤治疗公司。Countouriotis博士获得了加州大学洛杉矶分校的学士学位和塔夫茨大学医学院的医学博士学位。她在加州大学洛杉矶分校接受了最初的儿科培训，并在Fred Hutchinson癌症研究中心接受了儿科血液学/肿瘤学项目的额外培训。
Athena Countouriotis has served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. since October 2018 and from May 2018 to September 2018 she served as Chief Medical Officer of Turning Point Therapeutics. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018 and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit's acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. Dr. Countouriotis currently serves on the boards of directors of Iovance Biotherapeutics, Inc. and Trovagene, Inc., both public oncology therapeutics companies. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program. - Athena Countouriotis自2018年10月起担任Turning Point医疗公司的首席执行官和董事会成员，并于2018年5月至2018年9月期间担任Turning Point医疗的首席医疗官。Countouriotis博士于2017年6月至2018年5月担任Adverum生物科技公司高级副总裁兼首席医疗官，在此之前于2015年1月至2017年5月担任奥洛兹美医疗公司高级副总裁兼首席医疗官。Countouriotis博士还从2012年2月起担任Ambit Biosciences Corporation的首席医疗官，直到2014年11月Ambit被Daiichi Sankyo公司收购。在她职业生涯的早期，Countouriotis博士曾领导辉瑞公司和百时美施贵宝公司内的多个肿瘤治疗临床开发组织。Countouriotis博士目前在Iovance Biotherapeutics，Inc.和Trovagene，Inc.的董事会任职，这两家公司都是上市的肿瘤治疗公司。Countouriotis博士获得了加州大学洛杉矶分校的学士学位和塔夫茨大学医学院的医学博士学位。她在加州大学洛杉矶分校接受了最初的儿科培训，并在Fred Hutchinson癌症研究中心接受了儿科血液学/肿瘤学项目的额外培训。
- Athena Countouriotis has served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. since October 2018 and from May 2018 to September 2018 she served as Chief Medical Officer of Turning Point Therapeutics. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018 and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit's acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. Dr. Countouriotis currently serves on the boards of directors of Iovance Biotherapeutics, Inc. and Trovagene, Inc., both public oncology therapeutics companies. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.
- Sheila Gujrathi
-
Sheila Gujrathi自2021年3月起担任Janux Therapeutics, Inc.的董事会成员。Sheila Gujrathi， 医学博士。加入BMS之前，2002至2008年，她就职于Genentech，担任免疫学、组织生长及修复临床发展项目职位；1999至2002年，担任McKinsey & Company保健业务的管理顾问，为保健和制药业项目提供战略意见。她在西北大学（Northwestern University）获得生物医学工程学学士学位、医学教育加速荣誉项目医学博士学位。她在哈佛大学Brigham and Women’s Hospital完成了内科实习和住院医师实习，现在是内科注册医师。她在加利福尼亚大学旧金山分校（University of California, San Francisco）和斯坦福大学（Stanford University）变态反应与免疫学项目得到额外培训。
Sheila Gujrathi,has served as a member of Board of Directors since March 2021. Dr. Gujrathi also serves as the Chairperson of the board of directors of Immpact Bio, a biopharmaceutical company, and as the Executive Chair of the board of directors of Ventyx Biosciences, a public biopharmaceutical company. Dr. Gujrathi previously served as Chair of the board of directors of ADARx Pharmaceuticals, Inc., a biopharmaceutical company, from June 2020 to January 2025, and on the board of directors of Turning Point Therapeutics, Inc., a public biopharmaceutical company, from November 2017 to March 2021, and as Chair of the board of directors from April 2019 to March 2021. Dr. Gujrathi also previously served on the board of directors of Five Prime Therapeutics, Inc. (acquired by Amgen in April 2021) from December 2015 to June 2019 and Ambrx, Inc. from February 2014 until its acquisition in June 2015. Dr. Gujrathi is a Co-Founder of Gossamer Bio, Inc., a public biopharmaceutical company, and served as President and Chief Executive Officer from July 2018 to November 2020 and as President and Chief Operating Officer from October 2015 to June 2018 and as a member of its board of directors from October 2015 to November 2020. Previously, Dr. Gujrathi was the Chief Medical Officer of Receptos, Inc., a biopharmaceutical company, a position she held from June 2011 until its acquisition by Celgene Corporation in August 2015. Dr. Gujrathi joined Receptos, Inc. from Bristol-Myers Squibb Company ("Bristol-Meyers Squibb"), where she was Vice President of the Global Clinical Research Group in Immunology from 2008 until 2011. Prior to joining Bristol-Myers Squibb, Dr. Gujrathi worked at Genentech, Inc., where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from 2002 until 2008. From 1999 until 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. in Biomedical Engineering and an M.D. from Northwestern University in Medical Education. Dr. Gujrathi completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School and is board certified in internal medicine. Dr. Gujrathi received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program. - Sheila Gujrathi自2021年3月起担任Janux Therapeutics, Inc.的董事会成员。Sheila Gujrathi， 医学博士。加入BMS之前，2002至2008年，她就职于Genentech，担任免疫学、组织生长及修复临床发展项目职位；1999至2002年，担任McKinsey & Company保健业务的管理顾问，为保健和制药业项目提供战略意见。她在西北大学（Northwestern University）获得生物医学工程学学士学位、医学教育加速荣誉项目医学博士学位。她在哈佛大学Brigham and Women’s Hospital完成了内科实习和住院医师实习，现在是内科注册医师。她在加利福尼亚大学旧金山分校（University of California, San Francisco）和斯坦福大学（Stanford University）变态反应与免疫学项目得到额外培训。
- Sheila Gujrathi,has served as a member of Board of Directors since March 2021. Dr. Gujrathi also serves as the Chairperson of the board of directors of Immpact Bio, a biopharmaceutical company, and as the Executive Chair of the board of directors of Ventyx Biosciences, a public biopharmaceutical company. Dr. Gujrathi previously served as Chair of the board of directors of ADARx Pharmaceuticals, Inc., a biopharmaceutical company, from June 2020 to January 2025, and on the board of directors of Turning Point Therapeutics, Inc., a public biopharmaceutical company, from November 2017 to March 2021, and as Chair of the board of directors from April 2019 to March 2021. Dr. Gujrathi also previously served on the board of directors of Five Prime Therapeutics, Inc. (acquired by Amgen in April 2021) from December 2015 to June 2019 and Ambrx, Inc. from February 2014 until its acquisition in June 2015. Dr. Gujrathi is a Co-Founder of Gossamer Bio, Inc., a public biopharmaceutical company, and served as President and Chief Executive Officer from July 2018 to November 2020 and as President and Chief Operating Officer from October 2015 to June 2018 and as a member of its board of directors from October 2015 to November 2020. Previously, Dr. Gujrathi was the Chief Medical Officer of Receptos, Inc., a biopharmaceutical company, a position she held from June 2011 until its acquisition by Celgene Corporation in August 2015. Dr. Gujrathi joined Receptos, Inc. from Bristol-Myers Squibb Company ("Bristol-Meyers Squibb"), where she was Vice President of the Global Clinical Research Group in Immunology from 2008 until 2011. Prior to joining Bristol-Myers Squibb, Dr. Gujrathi worked at Genentech, Inc., where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from 2002 until 2008. From 1999 until 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. in Biomedical Engineering and an M.D. from Northwestern University in Medical Education. Dr. Gujrathi completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School and is board certified in internal medicine. Dr. Gujrathi received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.
高管简历
中英对照 | 中文 | 英文- Annette North
Annette North，自2015年3月合并起担任高级副总裁兼总顾问；2015年1月至2015年3月上游兼并期间担任Prior Kura的高级副总裁兼总顾问。她也是Wellspring Biosciences LLC及其母公司Araxes Pharma LLC的总顾问兼秘书。在加入我公司之前，2013年6月至2015年1月间，她是Ambit Biosciences Corporation（上市生物制药公司）的高级副总裁兼总顾问，在此期间Ambit完成了其首次公开发售，被Daiichi Sankyo Company Limited收购；2009年1月至2014年12月间担任多家生命科学公司的独立法律顾问；2000年至2008年，她是SGX Pharmaceuticals, Inc.（上市生物制药公司，2008年被Eli Lilly and Company收购）的总顾问，并担任多项其他职位。她早期曾担任Axys Pharmaceuticals, Inc.（生物制药公司）的运营及法律高级主管、Sequana Therapeutics, Inc.（生物制药公司）的法律事务主管。她获得了澳大利亚the University of Melbourne商学和法学双学士学位。
Annette North has been appointed to serve as our Executive Vice President, General Counsel and Secretary effective April 15 2019. Previously, Ms. North served as Senior Vice President, General Counsel of Kura Oncology, Inc., a publicly held clinical-stage biopharmaceutical company, from January 2015 to April 2019 and as General Counsel and Secretary of Wellspring Biosciences, Inc. and its parent company, Araxes Pharma LLC. Ms. North served as Senior Vice President and General Counsel of Ambit Biosciences Corporation, a publicly held biopharmaceutical company, from June 2013 to January 2015 during which time Ambit completed its initial public offering and was acquired by Daiichi Sankyo Company Limited. From January 2009 to December 2014 Ms. North was an independent legal consultant to a number of life sciences companies. From 2000 to 2008 Ms. North served as General Counsel and held a number of other positions at SGX Pharmaceuticals, Inc., a publicly held biopharmaceutical company which was acquired by Eli Lilly and Company in 2008. Earlier in her career, Ms. North served as Senior Director of Operations and Legal at Axys Pharmaceuticals, Inc., a biopharmaceutical company, and Director of Legal Affairs at Sequana Therapeutics, Inc., a biopharmaceutical company. Ms. North received both her Bachelor of Commerce and her Bachelor of Laws from the University of Melbourne, Australia.- Annette North，自2015年3月合并起担任高级副总裁兼总顾问；2015年1月至2015年3月上游兼并期间担任Prior Kura的高级副总裁兼总顾问。她也是Wellspring Biosciences LLC及其母公司Araxes Pharma LLC的总顾问兼秘书。在加入我公司之前，2013年6月至2015年1月间，她是Ambit Biosciences Corporation（上市生物制药公司）的高级副总裁兼总顾问，在此期间Ambit完成了其首次公开发售，被Daiichi Sankyo Company Limited收购；2009年1月至2014年12月间担任多家生命科学公司的独立法律顾问；2000年至2008年，她是SGX Pharmaceuticals, Inc.（上市生物制药公司，2008年被Eli Lilly and Company收购）的总顾问，并担任多项其他职位。她早期曾担任Axys Pharmaceuticals, Inc.（生物制药公司）的运营及法律高级主管、Sequana Therapeutics, Inc.（生物制药公司）的法律事务主管。她获得了澳大利亚the University of Melbourne商学和法学双学士学位。
- Annette North has been appointed to serve as our Executive Vice President, General Counsel and Secretary effective April 15 2019. Previously, Ms. North served as Senior Vice President, General Counsel of Kura Oncology, Inc., a publicly held clinical-stage biopharmaceutical company, from January 2015 to April 2019 and as General Counsel and Secretary of Wellspring Biosciences, Inc. and its parent company, Araxes Pharma LLC. Ms. North served as Senior Vice President and General Counsel of Ambit Biosciences Corporation, a publicly held biopharmaceutical company, from June 2013 to January 2015 during which time Ambit completed its initial public offering and was acquired by Daiichi Sankyo Company Limited. From January 2009 to December 2014 Ms. North was an independent legal consultant to a number of life sciences companies. From 2000 to 2008 Ms. North served as General Counsel and held a number of other positions at SGX Pharmaceuticals, Inc., a publicly held biopharmaceutical company which was acquired by Eli Lilly and Company in 2008. Earlier in her career, Ms. North served as Senior Director of Operations and Legal at Axys Pharmaceuticals, Inc., a biopharmaceutical company, and Director of Legal Affairs at Sequana Therapeutics, Inc., a biopharmaceutical company. Ms. North received both her Bachelor of Commerce and her Bachelor of Laws from the University of Melbourne, Australia.
- Brian Baker
Brian Baker自2017年7月起担任我们的财务和行政Vice President。此前，贝克先生于2013年2月至2017年7月担任Cleave Biosciences，Inc.财务Vice President。从2011年到2013年，Baker先生担任生命科学行业多家公司的独立财务顾问。从2006年到2010年，Baker先生在Phenomix Corporation担任越来越重要的职务，包括Vice President财务和首席会计官。Baker从2000年到2006年在Cengent Therapeutics，Inc.（之前是Structural BioInformatics，Inc.）担任多个职位。Baker先生从1996年到2000年在普华永道会计师事务所（Price Waterhouse）开始了他的会计职业生涯。Baker先生在圣地亚哥州立大学（San Diego State University）获得工商管理会计学士学位和工商管理信息系统硕士学位。Baker先生在加利福尼亚州（California）拥有活跃的注册会计师执照。
Brian Baker has served as our Vice President of Finance and Administration since July 2017. Previously, Mr. Baker served as the Vice President, Finance at Cleave Biosciences, Inc. from February 2013 until July 2017. From 2011 through 2013 Mr. Baker worked as an independent finance consultant to multiple companies in the life science industry. From 2006 through 2010 Mr. Baker held positions of increasing responsibility, including Vice President Finance and Principal Accounting Officer, with Phenomix Corporation. From 2000 through 2006 Mr. Baker held positions of increasing responsibility with Cengent Therapeutics, Inc. previously Structural Bioinformatics, Inc.. Mr. Baker began his accounting career with PricewaterhouseCoopers (previously Price Waterhouse) from 1996 through 2000. Mr. Baker received a B.S. in Business Administration-Accounting and an M.S. in Business Administration-Information Systems from San Diego State University. Mr. Baker maintains an active certified public accounting license in the state of California.- Brian Baker自2017年7月起担任我们的财务和行政Vice President。此前，贝克先生于2013年2月至2017年7月担任Cleave Biosciences，Inc.财务Vice President。从2011年到2013年，Baker先生担任生命科学行业多家公司的独立财务顾问。从2006年到2010年，Baker先生在Phenomix Corporation担任越来越重要的职务，包括Vice President财务和首席会计官。Baker从2000年到2006年在Cengent Therapeutics，Inc.（之前是Structural BioInformatics，Inc.）担任多个职位。Baker先生从1996年到2000年在普华永道会计师事务所（Price Waterhouse）开始了他的会计职业生涯。Baker先生在圣地亚哥州立大学（San Diego State University）获得工商管理会计学士学位和工商管理信息系统硕士学位。Baker先生在加利福尼亚州（California）拥有活跃的注册会计师执照。
- Brian Baker has served as our Vice President of Finance and Administration since July 2017. Previously, Mr. Baker served as the Vice President, Finance at Cleave Biosciences, Inc. from February 2013 until July 2017. From 2011 through 2013 Mr. Baker worked as an independent finance consultant to multiple companies in the life science industry. From 2006 through 2010 Mr. Baker held positions of increasing responsibility, including Vice President Finance and Principal Accounting Officer, with Phenomix Corporation. From 2000 through 2006 Mr. Baker held positions of increasing responsibility with Cengent Therapeutics, Inc. previously Structural Bioinformatics, Inc.. Mr. Baker began his accounting career with PricewaterhouseCoopers (previously Price Waterhouse) from 1996 through 2000. Mr. Baker received a B.S. in Business Administration-Accounting and an M.S. in Business Administration-Information Systems from San Diego State University. Mr. Baker maintains an active certified public accounting license in the state of California.
- Jingrong Jean Cui
Jingrong Jean Cui是Turning Point Therapeutics的联合创始人，自2013年10月以来一直担任我们的首席科学官和董事会成员。崔博士于2018年4月至2019年1月担任我们的总裁。2018年9月，崔博士成为我们的董事会主席。从2003年到2013年，崔博士是辉瑞公司的高级首席科学家，然后是副研究员。从1999年到2003年，崔博士担任Sugen，Inc.（一家制药公司）的项目负责人和集团负责人。从1997年到1999年，崔博士是Corvas International，Inc.的研究科学家。从1995年到1997年，崔博士是Glycomed，Inc.的研究科学家。从1994年到1995年，崔博士是劳伦斯伯克利国家实验室和加州大学伯克利分校的博士后。崔博士在俄亥俄州立大学获得博士学位，并在中国科学技术大学获得工商管理硕士学位。
Jingrong Jean Cui is a co-founder of Turning Point Therapeutics, and has served as our Chief Scientific Officer and a member of our board of directors since October 2013. Dr. Cui served as our President from April 2018 until January 2019. In September 2018 Dr. Cui became Chair of our board of directors. From 2003 until 2013 Dr. Cui was Senior Principal Scientist and then Associate Research Fellow at Pfizer. From 1999 until 2003 Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation. From 1997 until 1999 Dr. Cui was a research scientist at Corvas International, Inc. From 1995 until 1997 Dr. Cui was a research scientist at Glycomed, Inc. From 1994 until 1995 Dr. Cui was a postdoctoral fellow at Lawrence Berkeley National Laboratory and the University of California Berkeley. Dr. Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the University of Science and Technology of China.- Jingrong Jean Cui是Turning Point Therapeutics的联合创始人，自2013年10月以来一直担任我们的首席科学官和董事会成员。崔博士于2018年4月至2019年1月担任我们的总裁。2018年9月，崔博士成为我们的董事会主席。从2003年到2013年，崔博士是辉瑞公司的高级首席科学家，然后是副研究员。从1999年到2003年，崔博士担任Sugen，Inc.（一家制药公司）的项目负责人和集团负责人。从1997年到1999年，崔博士是Corvas International，Inc.的研究科学家。从1995年到1997年，崔博士是Glycomed，Inc.的研究科学家。从1994年到1995年，崔博士是劳伦斯伯克利国家实验室和加州大学伯克利分校的博士后。崔博士在俄亥俄州立大学获得博士学位，并在中国科学技术大学获得工商管理硕士学位。
- Jingrong Jean Cui is a co-founder of Turning Point Therapeutics, and has served as our Chief Scientific Officer and a member of our board of directors since October 2013. Dr. Cui served as our President from April 2018 until January 2019. In September 2018 Dr. Cui became Chair of our board of directors. From 2003 until 2013 Dr. Cui was Senior Principal Scientist and then Associate Research Fellow at Pfizer. From 1999 until 2003 Dr. Cui served as Project Leader and Group Leader at SUGEN, Inc., a Pharmacia Corporation. From 1997 until 1999 Dr. Cui was a research scientist at Corvas International, Inc. From 1995 until 1997 Dr. Cui was a research scientist at Glycomed, Inc. From 1994 until 1995 Dr. Cui was a postdoctoral fellow at Lawrence Berkeley National Laboratory and the University of California Berkeley. Dr. Cui received her Ph.D. from The Ohio State University, and her M.S. and B.S. from the University of Science and Technology of China.
- Athena Countouriotis
Athena Countouriotis自2018年10月起担任Turning Point医疗公司的首席执行官和董事会成员，并于2018年5月至2018年9月期间担任Turning Point医疗的首席医疗官。Countouriotis博士于2017年6月至2018年5月担任Adverum生物科技公司高级副总裁兼首席医疗官，在此之前于2015年1月至2017年5月担任奥洛兹美医疗公司高级副总裁兼首席医疗官。Countouriotis博士还从2012年2月起担任Ambit Biosciences Corporation的首席医疗官，直到2014年11月Ambit被Daiichi Sankyo公司收购。在她职业生涯的早期，Countouriotis博士曾领导辉瑞公司和百时美施贵宝公司内的多个肿瘤治疗临床开发组织。Countouriotis博士目前在Iovance Biotherapeutics，Inc.和Trovagene，Inc.的董事会任职，这两家公司都是上市的肿瘤治疗公司。Countouriotis博士获得了加州大学洛杉矶分校的学士学位和塔夫茨大学医学院的医学博士学位。她在加州大学洛杉矶分校接受了最初的儿科培训，并在Fred Hutchinson癌症研究中心接受了儿科血液学/肿瘤学项目的额外培训。
Athena Countouriotis has served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. since October 2018 and from May 2018 to September 2018 she served as Chief Medical Officer of Turning Point Therapeutics. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018 and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit's acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. Dr. Countouriotis currently serves on the boards of directors of Iovance Biotherapeutics, Inc. and Trovagene, Inc., both public oncology therapeutics companies. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.- Athena Countouriotis自2018年10月起担任Turning Point医疗公司的首席执行官和董事会成员，并于2018年5月至2018年9月期间担任Turning Point医疗的首席医疗官。Countouriotis博士于2017年6月至2018年5月担任Adverum生物科技公司高级副总裁兼首席医疗官，在此之前于2015年1月至2017年5月担任奥洛兹美医疗公司高级副总裁兼首席医疗官。Countouriotis博士还从2012年2月起担任Ambit Biosciences Corporation的首席医疗官，直到2014年11月Ambit被Daiichi Sankyo公司收购。在她职业生涯的早期，Countouriotis博士曾领导辉瑞公司和百时美施贵宝公司内的多个肿瘤治疗临床开发组织。Countouriotis博士目前在Iovance Biotherapeutics，Inc.和Trovagene，Inc.的董事会任职，这两家公司都是上市的肿瘤治疗公司。Countouriotis博士获得了加州大学洛杉矶分校的学士学位和塔夫茨大学医学院的医学博士学位。她在加州大学洛杉矶分校接受了最初的儿科培训，并在Fred Hutchinson癌症研究中心接受了儿科血液学/肿瘤学项目的额外培训。
- Athena Countouriotis has served as Chief Executive Officer and a member of the board of directors of Turning Point Therapeutics Inc. since October 2018 and from May 2018 to September 2018 she served as Chief Medical Officer of Turning Point Therapeutics. Dr. Countouriotis served as Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018 and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017. Dr. Countouriotis also served as Chief Medical Officer of Ambit Biosciences Corporation from February 2012 until Ambit's acquisition by Daiichi Sankyo Company in November 2014. Earlier in her career, Dr. Countouriotis led various clinical development organizations within Pfizer Inc. and Bristol-Myers Squibb Company for oncology therapeutics. Dr. Countouriotis currently serves on the boards of directors of Iovance Biotherapeutics, Inc. and Trovagene, Inc., both public oncology therapeutics companies. Dr. Countouriotis earned a B.S. from the University of California, Los Angeles, and an M.D. from Tufts University School of Medicine. She received her initial training in pediatrics at the University of California, Los Angeles, and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program.